Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Newron Pharmaceuticals S.p.A. (NWPHF) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Newron Pharmaceuticals is a biopharmaceutical company with its focus on novel therapies for central nervous system diseases and pain. Currently, Phase III trials of safinamide are ongoing for the treatment of Parkinson’s disease, which Merck Serono has exclusive global rights to develop, manufacture and commercialize. Newron is also evaluating the further clinical development of ralfinamide for pain and psychiatric diseases and has other projects at various stages of preclinical and clinical development. For more information, visit the company’s Web site at

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit

Let us hear your thoughts below:

This entry was posted in BIO Conference. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *